NCT07157839 Phosphorylated Tau Levels in Donated Blood
| NCT ID | NCT07157839 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Texas Health Science Center, Houston |
| Condition | Alzheimer&Amp;#39;s Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-08-28 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2025-08-28 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.
Eligibility Criteria
Inclusion Criteria: * The plasma sample from donators. Exclusion Criteria: * None.
Contact & Investigator
Zhongcong Xie, M.D., Ph.D.
PRINCIPAL INVESTIGATOR
The University of Texas Health Science Center, Houston
Frequently Asked Questions
Who can join the NCT07157839 clinical trial?
This trial is open to participants of all sexes, studying Alzheimer&Amp;#39;s Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07157839 currently recruiting?
Yes, NCT07157839 is actively recruiting participants. Contact the research team at Zhongcong.Xie@uth.tmc.edu for enrollment information.
Where is the NCT07157839 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07157839 clinical trial?
NCT07157839 is sponsored by The University of Texas Health Science Center, Houston. The principal investigator is Zhongcong Xie, M.D., Ph.D. at The University of Texas Health Science Center, Houston. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.